Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.34 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536675 | 0.85 | ABCG2 (0.41) | ABCG2GSK3BLMNAALDH1A1POLB | |
| SCHEMBL7416843 | 0.85 | ABCG2 (0.41) | ABCG2GSK3BLMNAALDH1A1POLB | |
| SCHEMBL3819757 | 0.85 | ABCG2 (0.41) | ABCG2GSK3BLMNAALDH1A1POLB | |
| SCHEMBL761139 | 0.84 | ITGB2 (0.44) | CA2LMNAALDH1A1ALOX12 | |
| SCHEMBL14521256 | 0.82 | ABCG2 (0.39) | ABCG2GSK3BLMNAALDH1A1POLB | |
| SCHEMBL12869360 | 0.81 | CA2 (0.38) | CA2LMNAALDH1A1MAOBGABRA1 | |
| SCHEMBL2278646 | 0.80 | GSK3B (0.39) | ABCG2GSK3BLMNAALDH1A1POLB | |
| SCHEMBL19738334 | 0.79 | EED (0.37) | ABCG2GSK3BLMNAALDH1A1POLB | |
| SCHEMBL10915836 | 0.78 | ABCG2 (0.43) | ABCG2GSK3BPOLBEEDMAOB | |
| SCHEMBL13058886 | 0.78 | CA2 (0.33) | ABCG2CA2LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ABCG2 337/4885CA2 3976/4885GSK3B 1929/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | ABCG2 3882/4885CA2 4349/4885GSK3B 3065/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | ABCG2 812/4885CA2 1193/4885GSK3B 1873/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ABCG2 337/4885CA2 3976/4885GSK3B 1929/4885 |
| US-20070191409-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ABCG2 893/4885CA2 142/4885GSK3B 321/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | ABCG2 2163/4885CA2 3236/4885GSK3B 584/4885 |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ABCG2 893/4885CA2 142/4885GSK3B 321/4885 |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | ABCG2 2347/4885CA2 1736/4885GSK3B 279/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ABCG2 893/4885CA2 142/4885GSK3B 321/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | ABCG2 32/4885CA2 4645/4885GSK3B 1235/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | ABCG2 2408/4885CA2 3359/4885GSK3B 2521/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ABCG2 233/4885CA2 1594/4885GSK3B 1489/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ABCG2 2552/4885CA2 4029/4885GSK3B 948/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | ABCG2 395/4885CA2 1041/4885GSK3B 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.